CDKN2A and head and neck squamous cell carcinoma: A prospective analysis of the association of tumor HPV status and therapeutic response and survival among 96 patients with stage III/IV HNSCC of oropharynx or larynx treated with IC followed by concurrent chemoradiotherapy on the ECOG 2399 phase II trial showed that patients with HPV-ISH-positive or p16-positive tumors had significantly higher response rates (RR) after IC and after paclitaxel-based chemoradiotherapy compared with patients with HPV-negative tumors.